Clinical Trial

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

Name: NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer — clinical trial record (NCT07595172)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Additionally, it will explore potential predictive and efficacy-related biomarkers.

Trial Details

NCT Number	NCT07595172
Lead Sponsor	West China Hospital Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions	Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer
Enrollment	55 participants
Start Date	2026-04
Primary Completion	2028-08 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-19